Pembrolizumab (trade name Keytruda) is a high-affinity humanized IgG4 anti-PD-1 antibody, it was the first treatment globally approved by the FDA for patients with metastatic melanoma [320] and the first therapy approved to treat all high-mutated solid tumors [321]. This evidence concerns the gene PDCD1 and metastatic melanoma.